Screener
UroGen Pharma URGN Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The source filing: UroGen Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 8:05 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025794
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Prepaid forward obligation | 125,135 | 127,276 |
| Long-term debt | 188,734 | 122,210 |
| Finance long-term lease liabilities | 2,939 | 3,475 |
| Operating long-term lease liabilities | 2,360 | 2,647 |
| Uncertain tax positions liability | 3,903 | 3,903 |
| Total liabilities | 384,986 | 305,929 |
| Commitments and contingencies (Note 19) | ||
| Shareholders' deficit: |
Item 1. Financial Statements.
FAQ
- What is UroGen Pharma's operating lease liabilities?
- UroGen Pharma (URGN) reported operating lease liabilities of $2.36M in Q2 2026.
- What is the long-term trend for UroGen Pharma's operating lease liabilities?
- Over 4 years (2020 to 2025), UroGen Pharma's operating lease liabilities has grown at a 15.3% compound annual growth rate (CAGR), from $1.5M to $2.65M.
- What does operating lease liabilities mean?
- Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.
Ask your AI about UroGen Pharma's operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude